Belgian consensus on metabolic problems associated with atypical antipsychotics

[en] A workshop was convened by a panel of psychiatrists, diabetologists and pharmacists from major Belgian hospitals to review the latest information relating to the risks with second-generation antipsychotics (SGA) for the development of metabolic disorders, especially impaired glucose tolerance, diabetes mellitus and dyslipidemia. The panelists sought to formulate recommendations for practising psychiatrists when initiating and maintaining therapy with SGA, and for the switch of SGA or initiation of further treatment if metabolic complications occur. In addition, recommendations for counselling of the patient and for the cooperation between the psychiatrist and the general physician or diabetologist, respectively, were provided.

Disciplines :

Endocrinology, metabolism & nutrition
Psychiatry

Author, co-author :

De Nayer, A.

De Hert, M.

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Van Gaal, L.

Peuskens, J.

Language :

English

Title :

Belgian consensus on metabolic problems associated with atypical antipsychotics

Publication date :

June 2005

Journal title :

International Journal of Psychiatry in Clinical Practice

ISSN :

1365-1501

eISSN :

1471-1788

Publisher :

Taylor & Francis As, Oslo, Norway

Volume :

Issue :

Pages :

130-137

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.informaworld.com/smpp/content~content=a714013020~db=all~order=page

Commentary :

International Journal of Psychiatry in Clinical Practice, 2005; 9(2): 130 /137

Available on ORBi :

since 19 February 2009

Statistics

Number of views

139 (2 by ULiège)

Number of downloads

496 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Consensus development conference on antipsychotic drugs and obesity and diabetes (2004) Diabetes Care, 27, pp. 596-601
'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: Consensus summary (2004) Br J Psychiatry, 184, pp. S112-4
De Hert, M., Van Eyck, D., Peuskens, H., Thys, E., Peuskens, J., Prevalence of impaired glucose tolerance in schizophrenic patients (2004) Annual Meeting of the American Psychiatric Society
Diagnosis and classification of diabetes mellitus (2004) Diabetes Care, 27, pp. S5-10
(1999) Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus, , Geneva
Palmer, J.P., Hirsch, I.B., What's in a name: Latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes (2003) Diabetes Care, 26, pp. 536-538
Tuomi, T., Groop, L., Zimmet, P., Rowley, M., Knowles, W., Mackay, I., Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease (1993) Diabetes, 42, pp. 359-362
Unwin, N., Shaw, J., Zimmet, P., Alberti, K.G., Impaired glucose tolerance and impaired fasting glycaemia: The current status on definition and intervention (2002) Diabet Med, 19, pp. 708-723
Mukherjee, S., Decina, P., Bocola, V., Saraceni, F., Scapicchio, P.L., Diabetes mellitus in schizophrenic patients (1996) Compr Psychiatry, 37, pp. 68-73
Subramaniam, M., Chong, S.A., Pek, E., Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia (2003) Can J Psychiatry, 48, pp. 345-347
Dynes, J.B., Diabetes in schizophrenia and diabetes in non-psychotic medical patients (1969) Dis Nerv Syst, 30, pp. 341-344
Citrome, L.L., Jaffe, A.B., Relationship of atypical antipsychotics with development of diabetes mellitus (2003) Ann Pharmacother, 37, pp. 1849-1857
Henderson, D.C., Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence? (2002) CNS Drugs, 16, pp. 77-89
Gianfrancesco, F.D., Grogg, A.L., Mahmoud, R.A., Wang, R.H., Nasrallah, H.A., Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database (2002) J Clin Psychiatry, 63, pp. 920-930
Clark, C., Burge, M.R., Diabetes mellitus associated with atypical anti-psychotic medications (2003) Diabetes Technol Ther, 5, pp. 669-683
Koro, C.E., Fedder, D.O., L'Italien, G.J., Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case-control study (2002) Br Med J, 325, p. 243
Sernyak, M.J., Leslie, D.L., Alarcon, R.D., Losonczy, M.F., Rosenheck, R., Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia (2002) Am J Psychiatry, 159, pp. 561-566
Caro, J.J., Ward, A., Levinton, C., Robinson, K., The risk of diabetes during olanzapine use compared with risperidone use: A retrospective database analysis (2002) J Clin Psychiatry, 63, pp. 1135-1139
Melkersson, K., Dahl, M.L., Adverse metabolic effects associated with atypical antipsychotics: Literature review and clinical implications (2004) Drugs, 64, pp. 701-723
Meyer, J.M., Koro, C.E., The effects of antipsychotic therapy on serum lipids: A comprehensive review (2004) Schizophr Res, 70, pp. 1-17
Jin, H., Meyer, J.M., Jeste, D.V., Atypical antipsychotics and glucose dysregulation: A systematic review (2004) Schizophr Res, 71, pp. 195-212
Casey, D.E., Haupt, D.W., Newcomer, J.W., Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patient with schizophrenia (2004) J Clin Psychiatry, 65, pp. 4-18
Scheen, A., De Hert, M., Risque de diabete sucre sous antipsychotiques atyptiques (2004) Méd Hyg, pp. 1591-1596
Hedenmalm, K., Hagg, S., Stahl, M., Mortimer, O., Spigset, O., Glucose intolerance with atypical antipsychotics (2002) Drug Saf, 25, pp. 1107-1116
Koller, E., Schneider, B., Bennett, K., Dubitsky, G., Clozapine-associated diabetes (2001) Am J Med, 111, pp. 716-723
Koller, E.A., Doraiswamy, P.M., Olanzapine-associated diabetes mellitus (2002) Pharmacotherapy, 22, pp. 841-852
Koller, E.A., Cross, J.T., Doraiswamy, P.M., Schneider, B.S., Risperidone-associated diabetes mellitus: A pharmacovigilance study (2003) Pharmacotherapy, 23, pp. 735-744
Koller, E.A., Weber, J., Doraiswamy, P.M., Schneider, B.S., A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus (2004) J Clin Psychiatry, 65, pp. 857-863
Consensus development conference on antipsychotic drugs and obesity and diabetes (2004) J Clin Psychiatry, 65, pp. 267-272
Grundy, S.M., Brewer Jr., H.B., Cleeman, J.I., Smith Jr., S.C., Lenfant, C., Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition (2004) Circulation, 109, pp. 433-438
Haupt, D.W., Newcomer, J.W., Hyperglycemia and antipsychotic medications (2001) J Clin Psychiatry, 62 (SUPPL. 27), pp. 15-26. , discussion 40-1
Henderson, D., (2003) Medical Illness and Schizophrenia, , Meyer J, Nasrallah H, editors. Washington, DC: Am Psy Publishing
Marder, S.R., Essock, S.M., Miller, A.L., Physical health monitoring of patients with schizophrenia (2004) Am J Psychiatry, 161, pp. 1334-1349
Koro, C.E., Bowlin, S.J., Bourgeois, N., Fedder, D.O., Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report (2004) Diabetes Care, 27, pp. 17-20
Nasrallah, H., Korn, M., (2004) Metabolic Disorders in Schizophrenia: Relationship to Atypical Antipsychotic Treatment, , posted 07/28/2004: Medscape Psychiatry and Mental Health schizophrenia expert column
Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) J Am Med Assoc, 285, pp. 2486-2497
Cohn, T., Wolever, T., Zipursky, R., Screening for diabetes and impaired glucose tolerance in patients on antipsychotic medication (2002) J Neuropsychopharmacol, 5 (SUPPL. I), p. 168
Rosack, J., FDA to require diabetes warning on antipsychotics (2003) Psychiatr News, 38. , 1-a-27
Haffher, S.M., Miettinen, H., Stern, M.P., The homeostasis model in the San Antonio Heart Study (1997) Diabetes Care, 20, pp. 1087-1092
Standards of medical care for patients with diabetes mellitus (2002) Diabetes Care, 26 (SUPPL. 1), pp. 33-50
Gough, S., Pelever, R., Diabetes and its prevention: Pragmatic solutions for people with schizophrenia (2004) Br J Psychiatr, 184, pp. S106-11
Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (2002) New Engl J Med, 346, pp. 393-403
Regenold, W.T., Thapar, R.K., Marano, C., Gavirneni, S., Kondapavuluru, P.V., Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use (2002) J Affect Disord, 70, pp. 19-26
Gianfrancesco, F., Grogg, A., Mahmoud, R., Wang, R.H., Meletiche, D., Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders (2003) Clin Ther, 25, pp. 1150-1171
Genuth, S., Alberti, K.G., Bennett, P., Follow-up report on the diagnosis of diabetes mellitus (2003) Diabetes Care, 26, pp. 3160-3167